Drug
Sirolimus (rapamycin)
Sirolimus (rapamycin) is a pharmaceutical drug with 4 clinical trials. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 3 completed trials
Completion Rate
100%(3/3)
Active Trials
0(0%)
Results Posted
67%(2 trials)
Phase Distribution
Ph phase_1
4
100%
Phase Distribution
4
Early Stage
0
Mid Stage
0
Late Stage
Phase Distribution4 total trials
Phase 1Safety & dosage
4(100.0%)
Highest Phase Reached
Phase 1Trial Status & Enrollment
Completion Rate
100.0%
3 of 3 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
4
all time
Status Distribution
Active(1)
Completed(3)
Detailed Status
Completed3
Not yet recruiting1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
Phase 1
Trials by Phase
Phase 14 (100.0%)
Trials by Status
not_yet_recruiting125%
completed375%
Recent Activity
0 active trials
Showing 4 of 4
not_yet_recruitingphase_1
Effects of Sirolimus on Asymptomatic ApoE4 Carriers
NCT07728175
completedphase_1
Sirolimus as Therapeutic Approach to Uveitis
NCT00908466
completedphase_1
Trial of Continuous Once Daily Oral Treatment Using BIBW 2992 (Afatinib) Plus Sirolimus (Rapamune®) in Patients With Non-small Cell Lung Cancer Harbouring an EGFR Mutation and/or Disease Progression Following Prior Erlotinib or Gefitinib
NCT00993499
completedphase_1
Docetaxel and Sirolimus in Patients With Advanced Malignancies
NCT01054313
Clinical Trials (4)
Showing 4 of 4 trials
NCT07728175Phase 1
Effects of Sirolimus on Asymptomatic ApoE4 Carriers
NCT00908466Phase 1
Sirolimus as Therapeutic Approach to Uveitis
NCT00993499Phase 1
Trial of Continuous Once Daily Oral Treatment Using BIBW 2992 (Afatinib) Plus Sirolimus (Rapamune®) in Patients With Non-small Cell Lung Cancer Harbouring an EGFR Mutation and/or Disease Progression Following Prior Erlotinib or Gefitinib
NCT01054313Phase 1
Docetaxel and Sirolimus in Patients With Advanced Malignancies
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4